RESUMO
Plants of the Suregada Roxb. ex Rottler (formerly Gelonium Roxb. ex Willd) are utilized to treat various ailments, namely, hepatic, gum diseases, pyrexia, eczema, and venereal diseases. This review links the reported compounds to ethnomedicinal uses through pharmacological activities. The compounds possess anticancer, anti-allergic, antibacterial, anti-inflammatory, antioxidant, and anti-HIV properties. From the previous reports, 32 known species of the Suregada genus have been investigated morphologically, and nine were investigated for their phytochemistry and pharmacology. Phytochemistry, ethnomedicinal, and pharmacological uses of the other 23 Suregada species are not known and/or not reported. In this review, abietane diterpenoids are the main compounds expressed by the Suregada, accounting for 71 of the 114 reported compounds. Ten triterpenoids and sterols, one aliphatic, two lignans, five flavonoids, and twenty-one nitrogen-containing compounds have been reported from the genus.
RESUMO
A novel cycloartanol (1) and an acylated Sutherlandioside D (2) together with two known cycloartane derivatives, Sutherlandioside B (3) and Sutherlandioside A (4), were isolated from the aerial parts of Sutherlandia frutescens. The structures of these compounds were established by a combination of 1- and 2-D NMR techniques and further confirmed by high resolution ToF mass spectrometry (HRToFMS). Preliminary biological studies were also conducted to assess the activity of different plant extracts, fractions and compounds on cytokine expression. Compounds 1 and 2 prompted an increase in IL-6 expression while compound 4 showed a reduced IL-6 expression compared to the controls. Compound 1 is an effective suppressor of IL-10 expression. The plant compounds inhibited the expression of the two cytokines, IL-10 and TNFα. The results of the assays suggested that some components in the plant extract influence the immune system by suppressing the expression of IL-6, IL-10 and TNFα.
